Lumos Pharma (id:6995 LUMO)
4.31 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 12:48:34 AM)
Exchange closed, opens in 1 day 8 hours
-0.77 USD (-0.77%)
-0.46 USD (-0.46%)
6.68 USD (6.68%)
78.10 USD (78.10%)
39.48 USD (39.48%)
172.78 USD (172.78%)
-88.98 USD (-88.98%)
-38.43 USD (-38.43%)
About Lumos Pharma
Market Capitalization 37.45M
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas.
| Headquarters (address) |
4200 Marathon Boulevard Austin 78756 TX United States |
| Phone | 512 215 2630 |
| Website | https://lumos-pharma.com |
| Employees | 33 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | LUMO |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 1.37 - 4.58 |
| Market Capitalization | 37.45M |
| P/E trailing | -1.03 |
| P/E forward | -2.00 |
| Price/Sale | 16.98 |
| Price/Book | 7.62 |
| Beta | 0.331 |
| EPS | -4.28 |
| EPS United States (ID:6, base:3403) | 24.22 |